<H1>Chapter DOI: 10.1186/s12868-016-0271-x<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>44</td></tr><tr><td>Springer references</td><td>4</td></tr><tr><td>Non Springer references</td><td>40</td></tr><tr><td>BibStructured Count</td><td width="10%">41</td></tr><tr><td>BibUnstructured Count</td><td width="10%">3</td></tr><tr><td>DOI already available in SpringerLink</td><td>34</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>1</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Kust N, Panteleev D, Mertsalov I, Savchenko E, Rybalkina E, et al. Availability of pre- and pro-regions of transgenic gdnf affects the ability to induce axonal sprout growth. Mol Neurobiol. 2015;51(3):1195&#8211;205.</td><td><a href=http://dx.doi.org/10.1007/s12035-014-8792-8>10.1007/s12035-014-8792-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Beck KD, Valverde J, Alexi T. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature. 1995;373(6512):339&#8211;41.</td><td><a href=http://dx.doi.org/10.1038/373339a0>10.1038/373339a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260(5111):1130&#8211;2.</td><td><a href=http://dx.doi.org/10.1126/science.8493557>10.1126/science.8493557</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Kearns CM, Gash DM. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 1995;672(1&#8211;2):104&#8211;11.</td><td><a href=http://dx.doi.org/10.1016/0006-8993(94)01366-P>10.1016/0006-8993(94)01366-P</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Sauer H, Rosenblad C, Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor &#946;3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci USA. 1995;92(19):8935&#8211;9.</td><td><a href=http://dx.doi.org/10.1073/pnas.92.19.8935>10.1073/pnas.92.19.8935</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Marco S, Canudas AM, Canals JM, Gavald&#224; N, P&#233;rez-Navarro E, Alberch J. Excitatory amino acids differentially regulate the expression of GDNF, neurturin, and their receptors in the adult rat striatum. Exp Neurol. 2002;174(2):243&#8211;52.</td><td><a href=http://dx.doi.org/10.1006/exnr.2001.7859>10.1006/exnr.2001.7859</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Nicole O, Ali C, Docagne F, Plawinski L, MacKenzie ET, Vivien D, Buisson A. Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway. J Neurosci. 2001;21(9):3024&#8211;33.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Tokumine J, Sugahara K, Kakinohana O, Marsala M. The spinal GDNF level is increased after transient spinal cord ischemia in the rat. Acta Neurochir Suppl. 2003;86:231&#8211;4.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-3-7091-0651-8_50>10.1007/978-3-7091-0651-8_50</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Year, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Granholm AC, Reyland M, Albeck D, Sanders L, Gerhardt G, Hoernig G, et al. Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J Neurosci. 2000;20(9):3182&#8211;90.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Batchelor PE, Liberatore GT, Porritt MJ, Donnan GA, Howells DW. Inhibition of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum. Eur J Neurosci. 2000;12(10):3462&#8211;8.</td><td><a href=http://dx.doi.org/10.1046/j.1460-9568.2000.00239.x>10.1046/j.1460-9568.2000.00239.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 1995;373(6512):335&#8211;9.</td><td><a href=http://dx.doi.org/10.1038/373335a0>10.1038/373335a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Cunningham LA, Su C. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson&#8217;s disease. Exp Neurol. 2002;174(2):230&#8211;42.</td><td><a href=http://dx.doi.org/10.1006/exnr.2002.7877>10.1006/exnr.2002.7877</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Behrstock S, Ebert A, McHugh J, Vosberg S, Moore J, Schneider B, et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther. 2006;1(13):379&#8211;88.</td><td><a href=http://dx.doi.org/10.1038/sj.gt.3302679>10.1038/sj.gt.3302679</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Biju K, Zhou Q, Li G, Imam SZ, Roberts JL, Morgan WW, et al. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson&#8217;s disease. Mol Ther. 2010;18(8):1536&#8211;44.</td><td><a href=http://dx.doi.org/10.1038/mt.2010.107>10.1038/mt.2010.107</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Haney MJ, Zhao Y, Harrison EB, Mahajan V, Ahmed S, He Z, et al. Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases. PLoS ONE. 2013;8(4):e61852.</td><td><a href=http://dx.doi.org/10.1371/journal.pone.0061852>10.1371/journal.pone.0061852</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Airavaara M, Pletnikova O, Doyle ME, Zhang YE, Troncoso JC, Liu QR. Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease. J Biol Chem. 2011;286(52):45093&#8211;102.</td><td><a href=http://dx.doi.org/10.1074/jbc.M111.310250>10.1074/jbc.M111.310250</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Lonka-Nevalaita L, Lume M, Leppanen S, Jokitalo E, Peranen J, Saarma M. Characterization of the intracellular localization, processing, and secretion of two glial cell line-derived neurotrophic factor splice isoforms. J Neurosci. 2010;30(34):11403&#8211;13.</td><td><a href=http://dx.doi.org/10.1523/JNEUROSCI.5888-09.2010>10.1523/JNEUROSCI.5888-09.2010</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Yokoyama H, Kuroiwa H, Kasahara J, Araki T. Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced mouse model of Parkinson&#8217;s disease. Acta Neurobiol. 2011;71(2):269&#8211;80.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Ugrumov MV, Khaindrava VG, Kozina EA, Kucheryanu VG, Bocharov EV, Kryzhanovsky GN, et al. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice. Neuroscience. 2011;181:175&#8211;88.</td><td><a href=http://dx.doi.org/10.1016/j.neuroscience.2011.03.007>10.1016/j.neuroscience.2011.03.007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Rozas G, Guerra MJ, Labandeira-Garc&#237;a JL. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Protoc. 1997;2(1):75&#8211;84.</td><td><a href=http://dx.doi.org/10.1016/S1385-299X(97)00034-2>10.1016/S1385-299X(97)00034-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Schulte EC, Winkelmann J. When Parkinson&#8217;s disease patients go to sleep: specific sleep disturbances related to Parkinson&#8217;s disease. J Neurol. 2011;258(Suppl 2):S328&#8211;35.</td><td><a href=http://dx.doi.org/10.1007/s00415-011-5933-0>10.1007/s00415-011-5933-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Kovalzon VM, Zavalko IM. The neurochemistry of the sleep&#8211;wakefulness cycle and Parkinson&#8217;s disease. Neurochem J. 2013;7(3):171&#8211;83.</td><td><a href=http://dx.doi.org/10.1134/S1819712413030069>10.1134/S1819712413030069</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Manolov AI, Dolgikh VV, Ukraintseva YuV, Zavalko IM, Revishchin AV, Pavlova GV, et al. Moving activity and wakefulness&#8211;sleep cycle changes in a mouse MPTP model of Parkinson&#8217;s disease. Ross Fiziol Zh Im I M Sechenova. 2014;100(11):1252&#8211;60.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Kovalzon VM, Ugrumov MV, Pronina TS, Dorokhov VB, Manolov AI, et al. Early stages of Parkinson&#8217;s disease: comparative characteristics of sleep&#8211;waking cycle in patients and model animals. Fiziol Cheloveka. 2015;41(6):114&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>GenBank</span>. <span style='background:#FF3300'>http://www.ncbi.nlm.nih.gov/nuccore/NM_000514.3</span>. Accessed 20 May <span style='background:#66FF66'>2016</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Fujita K, Lazarovici P, Guroff G. Regulation of the differentiation of PC12 pheochromocytoma cells. Environ Health Perspect. 1989;80:127&#8211;42.</td><td><a href=http://dx.doi.org/10.1289/ehp.8980127>10.1289/ehp.8980127</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#DDDDDD'>UTHSCSA</span> <span style='background:#BCBCBC'>ImageTool</span></span></aug>. <span style='background:#FF3300'>http://compdent.uthscsa.edu/dig/itdesc.html</span>. Accessed 20 May <span style='background:#66FF66'>2016</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Manolov AI, Kovalzon VM, Ukraintseva YV, Moiseenko LS, Dorokhov VB. Dependence of accuracy of automatic sleep scoring on spectral characteristics of mice EEG. J High Nerv Activ. 2015;65(4):1&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Monaca C, Laloux C, Jacquesson JM, Gel&#233; P, Mar&#233;chal X, Bordet R, et al. Vigilance states in a parkinsonian model, the MPTP mouse. Eur J Neurosci. 2004;20(9):2474&#8211;8.</td><td><a href=http://dx.doi.org/10.1111/j.1460-9568.2004.03694.x>10.1111/j.1460-9568.2004.03694.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>West MJ, Ostergaard K, Andreassen OA, Finsen B. Estimation of the number of somatostatin neurons in the striatum: an in situ hybridization study using the optical fractionator method. J Comp Neurol. 1996;370:11&#8211;22.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1096-9861(19960617)370:1&lt;11::AID-CNE2&gt;3.0.CO;2-O>10.1002/(SICI)1096-9861(19960617)370:1&lt;11::AID-CNE2&gt;3.0.CO;2-O</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>ImageJ</span>. <span style='background:#FF3300'>http://imagej.nih.gov/ij/index.html</span>. Accessed 28 Oct <span style='background:#66FF66'>2015</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Gill SS, Patel NK, Hotton GR, O&#8217;Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9(5):589&#8211;95.</td><td><a href=http://dx.doi.org/10.1038/nm850>10.1038/nm850</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Suter-Crazzolara C, Unsicker K. GDNF is expressed in two forms in many tissues outside the CNS. NeuroReport. 1994;5(18):2486&#8211;8.</td><td><a href=http://dx.doi.org/10.1097/00001756-199412000-00020>10.1097/00001756-199412000-00020</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Trupp M, Ryden M, Jornvall H, Funakoshi H, Timmusk T, Arenas E, et al. Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. J Cell Biol. 1995;130(1):137&#8211;48.</td><td><a href=http://dx.doi.org/10.1083/jcb.130.1.137>10.1083/jcb.130.1.137</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Matsushita N, Fujita Y, Tanaka M, Nagatsu T, Kiuchi K. Cloning and structural organization of the gene encoding the mouse glial cell line-derived neurotrophic factor, GDNF. Gene. 1997;203(2):149&#8211;57.</td><td><a href=http://dx.doi.org/10.1016/S0378-1119(97)00506-4>10.1016/S0378-1119(97)00506-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Grimm L, Holinski-Feder E, Teodoridis J, Scheffer B, Schindelhauer D, Meitinger T, et al. Analysis of the human GDNF gene reveals an inducible promoter, three exons, a triplet repeat within the 3&#8242;-UTR and alternative splice products. Hum Mol Genet. 1998;7(12):1873&#8211;86.</td><td><a href=http://dx.doi.org/10.1093/hmg/7.12.1873>10.1093/hmg/7.12.1873</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science. 2001;294(5548):1945&#8211;8.</td><td><a href=http://dx.doi.org/10.1126/science.1065057>10.1126/science.1065057</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature. 2004;427:843&#8211;8.</td><td><a href=http://dx.doi.org/10.1038/nature02319>10.1038/nature02319</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Teng HK, Teng KK, Lee R, Wright S, Tevar S, Almeida RD, et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci. 2005;25:5455&#8211;63.</td><td><a href=http://dx.doi.org/10.1523/JNEUROSCI.5123-04.2005>10.1523/JNEUROSCI.5123-04.2005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Yano H, Torkin R, Martin LA, Chao MV, Teng KK. Proneurotrophin-3 is a neuronal apoptotic ligand: evidence for retrograde-directed cell killing. J Neurosci. 2009;29:14790&#8211;802.</td><td><a href=http://dx.doi.org/10.1523/JNEUROSCI.2059-09.2009>10.1523/JNEUROSCI.2059-09.2009</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Sun XL, Chen BY, Xia Y, Wang JJ, Chen LW. Functional switch from pro-neurotrophins to mature neurotrophins. Curr Protein Pept Sci. 2013;14(7):617&#8211;25.</td><td><a href=http://dx.doi.org/10.2174/1389203711209070658>10.2174/1389203711209070658</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Piccinini E, Kalkkinen N, Saarma M, Runeberg-Roos P. Glial cell line-derived neurotrophic factor: characterization of mammalian posttranslational modifications. Ann Med. 2013;45:66&#8211;73.</td><td><a href=http://dx.doi.org/10.3109/07853890.2012.663927>10.3109/07853890.2012.663927</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Sun XL, Chen BY, Duan L, Xia Y, Luo ZJ, Wang JJ, et al. The proform of glia cell line-derived neurotrophic factor: a potentially biologically active protein. Mol Neurobiol. 2014;49(1):234&#8211;50.</td><td><a href=http://dx.doi.org/10.1007/s12035-013-8515-6>10.1007/s12035-013-8515-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Truong DD, Wolters EC. Recognition and management of Parkinson&#8217;s disease during the premotor (prodromal) phase. Expert Rev Neurother. 2009;9(6):847&#8211;57.</td><td><a href=http://dx.doi.org/10.1586/ern.09.50>10.1586/ern.09.50</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>